Several drugs are available for this route of administration, of which Lucentis® (ranibizumab), Eylea® (aflibercept), Beovu® (brolucizumab-dbll) and Ozurdex® are the most commonly used.
In the near future, a new molecule will also be available to stabilise a form of dry AMD called geographic atrophy.
We take care of all eye diseases,
from initial diagnosis to regular follow-up.
